Enlivex Therapeutics Ltd.
ENLV
$1.10
$0.065.77%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 167.44% | -21.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 75.73% | 4.45% | |||
| Operating Income | -75.73% | -4.45% | |||
| Income Before Tax | -98.92% | 15.96% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -98.92% | 15.96% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -98.92% | 15.96% | |||
| EBIT | -75.73% | -4.45% | |||
| EBITDA | -84.08% | -4.67% | |||
| EPS Basic | -88.14% | 22.79% | |||
| Normalized Basic EPS | -60.73% | 22.83% | |||
| EPS Diluted | -88.14% | 23.56% | |||
| Normalized Diluted EPS | -60.73% | 22.83% | |||
| Average Basic Shares Outstanding | 5.70% | 8.87% | |||
| Average Diluted Shares Outstanding | 5.70% | 8.87% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||